Patient Education
The POLAR Promise: Groundbreaking Survival Gains for Targeted Pancreatic Cancer Patients in Phase II Trial
Phase II trial of Pembrolizumab Immunotherapy and Olaparib (POLAR) trial new data presented at the European Society for Medical Oncology (ESMO) 202...
Launching the Gastric Cancer Project Promotion: A Step Forward in Patient Care
April 24, 2024 — The Recover with Us Association is thrilled to announce the launch of the Gastric Cancer Project Promotion, made possible by the...
EMA Approves New First-line Treatment Option for Metastatic Pancreatic Cancer
Irinotecan hydrochloride trihydrate (Onivyde pegylated liposomal) was approved in March 2024 by the European Medicines Agency (EMA). Indications: N...
Fruquintinib: A New Medicine for mCRC Recommended for Approval in Europe
DiCE supports the recommendation for approval of fruquintinib, a new medicine for metastatic colorectal cancer (mCRC). This medicine offers mCRC pa...
OECD Report Confirms Inequalities in Cancer
Cancer causes almost a quarter of all deaths in the EU27, Norway and Iceland, with five new cancer cases diagnosed every minute in 2022. Assessing ...
Positive Response to New Neoadjuvant Treatment Combination for Gastric and Gastroesophageal Cancer
In a recently published study conducted by the Netherlands Cancer Institute, patients with gastric (stomach) cancer or gastroesophageal junction (G...
Biomarkers and their Role in the Diagnosis and Treatment of Cholangiocarcinoma (CCA)
Researchers in Italy have written a helpful and very detailed review of biomarkers specific to iCCA. Biomarkers are measurable medical signs that c...
COR2ED’s New Resources on Advanced HCC
COR2ED is an independent medical education company that develops impactful educational programmes within specific therapeutic areas. They have rece...
Lynch Syndrome, the Most Common of the Rarest
Next month is Lynch Syndrome Day, also known as Hereditary Non-Polyposis Colorectal Cancer, so we will remind people that those who have Lynch synd...
Act4Biosimilars: The Action Plan and Deep Dive Report for Europe are Now Live!
Act4Biosimilars is a global initiative that aims to increase patient access to biologics by facilitating greater Approvability, Accessibility, Acce...
